Robert Langer: Edison of Medicine

The episode begins with Robert Langer reflecting on the interplay between magic and science, emphasizing how both can lead to surprising discoveries. He recounts his early career challenges, including multiple rejections from prestigious journals, which taught him the value of perseverance. Langer's early work with Judah Folkman on angiogenesis inhibitors laid the groundwork for future breakthroughs in cancer treatment, despite initial skepticism from the scientific community.

Langer outlines his significant contributions to biotechnology, particularly in drug delivery systems and tissue engineering. He highlights the development of Avastin, the first FDA-approved drug targeting blood vessel growth, which took 28 years from concept to approval. This underscores the lengthy and expensive nature of drug development, with costs exceeding $2 billion primarily due to human clinical trials. Langer's innovations have had a lasting impact, as evidenced by his high citation count and H index.

Despite the clear successes, the conversation lacks direct pushback from Lex, leaving some areas unexplored, such as the ethical implications of the patent system in drug accessibility. Langer's mention of the patent system's dual role in funding and restricting access to drugs could have been a point of contention, but it was not deeply probed. The episode also touches on the importance of combining scientific discoveries with business acumen to successfully launch startups, a synergy Langer has mastered with 40 companies under his belt.

The discussion concludes with a forward-looking perspective on the future of cancer research and the role of engineering and AI in various fields. Langer envisions a future where biology and engineering work hand in hand to develop more effective cancer treatments. He also anticipates AI's growing influence across different sectors, including food science. While the episode covers a broad range of topics, it leaves open questions about the balance between innovation and accessibility in the pharmaceutical industry.